clinical trial · NCT04483440
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
Choroideremia4D-110
brief summary
This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated virus (AAV) gene therapy, 4D-110, in male patients with genetically-confirmed Choroideremia (CHM).
started
Jun 2, 2020
primary completion
May 26, 2027
completion
Aug 31, 2027
last updated
May 22, 2025
detailed description
This is an open-label, Phase 1 study to evaluate safety and tolerability as well as preliminary efficacy of a single IVT injection of 4D-110 at three dose levels in male patients with genetically-confirmed CHM.
official title
Phase 1 Open-Label, Dose-Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intravitreal 4D-110 in Patients With Choroideremia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol